CN114127105B - 抗金属硫蛋白抗体及其用途 - Google Patents

抗金属硫蛋白抗体及其用途 Download PDF

Info

Publication number
CN114127105B
CN114127105B CN202080051788.2A CN202080051788A CN114127105B CN 114127105 B CN114127105 B CN 114127105B CN 202080051788 A CN202080051788 A CN 202080051788A CN 114127105 B CN114127105 B CN 114127105B
Authority
CN
China
Prior art keywords
antibody
ser
amino acid
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080051788.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN114127105A (zh
Inventor
麦克·莱内斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Priority to CN202411420348.6A priority Critical patent/CN119285765A/zh
Publication of CN114127105A publication Critical patent/CN114127105A/zh
Application granted granted Critical
Publication of CN114127105B publication Critical patent/CN114127105B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080051788.2A 2019-07-15 2020-07-15 抗金属硫蛋白抗体及其用途 Active CN114127105B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411420348.6A CN119285765A (zh) 2019-07-15 2020-07-15 抗金属硫蛋白抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874340P 2019-07-15 2019-07-15
US62/874,340 2019-07-15
PCT/US2020/042064 WO2021011608A1 (en) 2019-07-15 2020-07-15 Metallothionein antibodies and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411420348.6A Division CN119285765A (zh) 2019-07-15 2020-07-15 抗金属硫蛋白抗体及其用途

Publications (2)

Publication Number Publication Date
CN114127105A CN114127105A (zh) 2022-03-01
CN114127105B true CN114127105B (zh) 2024-10-29

Family

ID=71895285

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080051788.2A Active CN114127105B (zh) 2019-07-15 2020-07-15 抗金属硫蛋白抗体及其用途
CN202411420348.6A Pending CN119285765A (zh) 2019-07-15 2020-07-15 抗金属硫蛋白抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411420348.6A Pending CN119285765A (zh) 2019-07-15 2020-07-15 抗金属硫蛋白抗体及其用途

Country Status (12)

Country Link
US (1) US12466877B2 (https=)
EP (1) EP3999531A1 (https=)
JP (1) JP7669339B2 (https=)
KR (1) KR20220034811A (https=)
CN (2) CN114127105B (https=)
AU (1) AU2020315367A1 (https=)
BR (1) BR112022000705A2 (https=)
CA (1) CA3144014A1 (https=)
IL (1) IL289843A (https=)
MX (1) MX2022000642A (https=)
PH (1) PH12022550097A1 (https=)
WO (1) WO2021011608A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121002061A (zh) * 2023-01-12 2025-11-21 弗吉尼亚大学专利基金委员会 抗cith3抗体及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201290B (zh) * 2010-06-14 2016-09-28 莱克拉生物医学股份公司 S100a4抗体及其治疗用途
US20140141009A1 (en) * 2011-07-08 2014-05-22 Univeristy Of Connecticut Use of antagonists targeting metallothionein to treat intestinal inflammation
EP3740282B1 (en) * 2018-01-17 2025-03-26 University of Connecticut Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications;Lina Yang等;American Journal of Physiology Endocrinol and Metabolism;第294卷;E987-E992页 *

Also Published As

Publication number Publication date
PH12022550097A1 (en) 2022-11-21
CN119285765A (zh) 2025-01-10
AU2020315367A1 (en) 2022-02-03
US20220306731A1 (en) 2022-09-29
JP2022542805A (ja) 2022-10-07
JP7669339B2 (ja) 2025-04-28
BR112022000705A2 (pt) 2022-03-22
IL289843A (en) 2022-03-01
WO2021011608A1 (en) 2021-01-21
EP3999531A1 (en) 2022-05-25
MX2022000642A (es) 2022-03-11
CA3144014A1 (en) 2021-01-21
US12466877B2 (en) 2025-11-11
CN114127105A (zh) 2022-03-01
KR20220034811A (ko) 2022-03-18

Similar Documents

Publication Publication Date Title
JP6843090B2 (ja) 血清アルブミンに結合するタンパク質
CN114641495B (zh) Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
JP2019534281A (ja) 免疫グロブリン及びその使用
CN106102837A (zh) 经由细胞受体锚定使用具有天然架构的双特异性抗体改良的hiv‑1‑中和抗体效力和广度
JP2016520058A (ja) 抗グルカゴン受容体抗体およびその使用方法
WO2019120060A1 (zh) 结合人il-5的单克隆抗体、其制备方法和用途
TWI832847B (zh) Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
EP4585617A1 (en) Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
CN114127105B (zh) 抗金属硫蛋白抗体及其用途
WO2019096219A1 (zh) 一种人源化抗il-13抗体及其制备方法和应用
CN102834413A (zh) 代谢障碍的治疗
TWI842699B (zh) Gcgr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
JP6592600B2 (ja) 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
EA048185B1 (ru) Антитела к металлотионеину и их применение
CN119613548A (zh) APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
WO2025223473A1 (zh) 抗gdf-15抗体及其应用
TW202613177A (zh) Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
HK40102002A (zh) Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN117843784A (zh) 抗人cd73抗体或其抗原结合片段及其应用
HK40016223B (en) Gcgr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof
HK40015554A (en) Gipr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant